search
Back to results

Human Amniotic Epithelial Cells for Asherman's Syndrome

Primary Purpose

Asherman's Syndrome

Status
Unknown status
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
hAECs
biological amnion
Sponsored by
The Second Affiliated Hospital of Chongqing Medical University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asherman's Syndrome

Eligibility Criteria

20 Years - 40 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • 1. Hysteroscopy examination confirms intrauterine adhesions, II -III according to the American Fertility Society (AFS) classification of uterine adhesions;
  • 2. Regular Menstrual cycles and menstruation is normal before abortion or curettage;
  • 3. Having a clear desire to fertility;
  • 4. Normal blood coagulation, liver, heart, and kidney function, absence of HIV, Hepatitis B or C, syphilis and psychiatric pathology;
  • 5. Serum β-hCG is negative;
  • 6. Be willing to complete the study and sign the consent form.

Exclusion Criteria:

  • 1. Having a history of malignant tumor;
  • 2. Having other uterine diseases, such as, uterine fibroids, adenomyosis and uterine malformations;
  • 3. Hysteroscopic adhesiolysis more than 3 times in the past;
  • 4. Absence of peripheral vein access.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm 5

    Arm Type

    Experimental

    Placebo Comparator

    Experimental

    Experimental

    Experimental

    Arm Label

    biological amnion loaded with hAECs

    biological amnion

    intravenous infusion of hAECs

    intrauterine infusion of hAECs

    hydrogel loaded with hAECs

    Arm Description

    Biological amnion loaded with 100 million hAECs is placed into uterine cavity immediately after TCRA.

    Biological amnion is placed into uterine cavity immediately after TCRA.

    intravenous infusion of 100 million hAECs immediately after TCRA

    100 million hAECs is infused into uterine cavity immediately after TCRA.

    Hydrogel loaded with 100 million hAECs is infused into uterine cavity immediately after TCRA.

    Outcomes

    Primary Outcome Measures

    Menstrual blood volume
    Estimate the menstrual blood volume after surgery by the number of sanitary napkins per day and number of days, which will be compared with pre-operation.

    Secondary Outcome Measures

    Endometrial thickness
    Measure the endometrial thickness during periovulatory period on ultrasound by the same trained medical sonographers at 3 months after surgery, compared with pre-operation.
    Uterine volume
    Measure the uterine volume during periovulatory period on ultrasound by the same trained medical sonographers at 3 months after surgery, compared with pre-operation.
    Ongoing pregnancy rate
    A ongoing pregnancy means that at the 12th week of pregnancy, ultrasound reveals that the fetus had a heart beat and the size of the fetus is in consistent with the gestational week.

    Full Information

    First Posted
    July 13, 2017
    Last Updated
    July 19, 2017
    Sponsor
    The Second Affiliated Hospital of Chongqing Medical University
    Collaborators
    Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03223454
    Brief Title
    Human Amniotic Epithelial Cells for Asherman's Syndrome
    Official Title
    Safety and Therapeutic Effect of Human Amniotic Epithelial Cells in Severe Refractory Asherman's Syndrome
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2017
    Overall Recruitment Status
    Unknown status
    Study Start Date
    October 2017 (Anticipated)
    Primary Completion Date
    September 2019 (Anticipated)
    Study Completion Date
    March 2021 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    The Second Affiliated Hospital of Chongqing Medical University
    Collaborators
    Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    This project aims to investigate the safety and effectiveness of human amniotic epithelial cells in the treatment of the severe refractory Asherman's syndrome.
    Detailed Description
    Asherman's syndrome is a gynecological disorder caused by the destruction of the endometrium due to repeated or aggressive curettages and/or endometritis. As a result, there is a loss of functional endometrium in multiple areas and the uterine cavity is obliterated by intrauterine adhesions, which results in amenorrhea, hypomenorrhea, infertility and recurrent pregnancy loss. Transcervical resection of adhesion (TCRA) is the main treatment for Asherman's syndrome, so far the effect is usually poor in moderate to severe refractory cases. Human amniotic epithelial cells (hAECs) are derived from human amniotic epithelium. hAECs retain the characteristics approximating to embryonic stem cells. Animal experiments have shown that the endometrial thickness and fertility of mice were significantly improved after intrauterine therapy with amniotic epithelial cells. To further explore the role of hAECs in Asherman's syndrome patients, this project plans to evaluate the safety of hAECs provided by Chongqing iCELL Biotechnology Co.,Ltd., which is a subsidiary of Shanghai iCELL Biotechnology Co.,Ltd., and find an effective treatment protocol.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Asherman's Syndrome

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    50 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    biological amnion loaded with hAECs
    Arm Type
    Experimental
    Arm Description
    Biological amnion loaded with 100 million hAECs is placed into uterine cavity immediately after TCRA.
    Arm Title
    biological amnion
    Arm Type
    Placebo Comparator
    Arm Description
    Biological amnion is placed into uterine cavity immediately after TCRA.
    Arm Title
    intravenous infusion of hAECs
    Arm Type
    Experimental
    Arm Description
    intravenous infusion of 100 million hAECs immediately after TCRA
    Arm Title
    intrauterine infusion of hAECs
    Arm Type
    Experimental
    Arm Description
    100 million hAECs is infused into uterine cavity immediately after TCRA.
    Arm Title
    hydrogel loaded with hAECs
    Arm Type
    Experimental
    Arm Description
    Hydrogel loaded with 100 million hAECs is infused into uterine cavity immediately after TCRA.
    Intervention Type
    Biological
    Intervention Name(s)
    hAECs
    Intervention Description
    hAECs are provided by Chongqing iCELL Biotechnology Co.,Ltd., which is a subsidiary of Shanghai iCELL Biotechnology Co.,Ltd. The participants are blind to their arms because the surgery is done under anesthesia. After hysteroscopic adhesiolysis, subsequently oral antibiotics will be given for 3 days to prevent infection. Estrogen will be administrated for 3 cycles to stimulate the repair of endometrium after the surgery.
    Intervention Type
    Biological
    Intervention Name(s)
    biological amnion
    Intervention Description
    Biological amnion is purchased from JiangXi RuiJi BioTechnology Co.,Ltd. The participants are blind to their arms because the surgery is done under anesthesia. After hysteroscopic adhesiolysis, subsequently oral antibiotics will be given for 3 days to prevent infection. Estrogen will be administrated for 3 cycles to stimulate the repair of endometrium after the surgery.
    Primary Outcome Measure Information:
    Title
    Menstrual blood volume
    Description
    Estimate the menstrual blood volume after surgery by the number of sanitary napkins per day and number of days, which will be compared with pre-operation.
    Time Frame
    at 3 months
    Secondary Outcome Measure Information:
    Title
    Endometrial thickness
    Description
    Measure the endometrial thickness during periovulatory period on ultrasound by the same trained medical sonographers at 3 months after surgery, compared with pre-operation.
    Time Frame
    at 3 months
    Title
    Uterine volume
    Description
    Measure the uterine volume during periovulatory period on ultrasound by the same trained medical sonographers at 3 months after surgery, compared with pre-operation.
    Time Frame
    at 3 months
    Title
    Ongoing pregnancy rate
    Description
    A ongoing pregnancy means that at the 12th week of pregnancy, ultrasound reveals that the fetus had a heart beat and the size of the fetus is in consistent with the gestational week.
    Time Frame
    up to 24 months

    10. Eligibility

    Sex
    Female
    Gender Based
    Yes
    Minimum Age & Unit of Time
    20 Years
    Maximum Age & Unit of Time
    40 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: 1. Hysteroscopy examination confirms intrauterine adhesions, II -III according to the American Fertility Society (AFS) classification of uterine adhesions; 2. Regular Menstrual cycles and menstruation is normal before abortion or curettage; 3. Having a clear desire to fertility; 4. Normal blood coagulation, liver, heart, and kidney function, absence of HIV, Hepatitis B or C, syphilis and psychiatric pathology; 5. Serum β-hCG is negative; 6. Be willing to complete the study and sign the consent form. Exclusion Criteria: 1. Having a history of malignant tumor; 2. Having other uterine diseases, such as, uterine fibroids, adenomyosis and uterine malformations; 3. Hysteroscopic adhesiolysis more than 3 times in the past; 4. Absence of peripheral vein access.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Lina Hu
    Phone
    86-23-63693707
    Email
    cqhulina@126.com
    First Name & Middle Initial & Last Name or Official Title & Degree
    Chanyu Zhang
    Phone
    86-23-63693296
    Email
    1317954623@qq.com
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Lina Hu
    Organizational Affiliation
    The Second Affiliated Hospital of Chongqing Medical University
    Official's Role
    Study Chair
    First Name & Middle Initial & Last Name & Degree
    Chanyu Zhang
    Organizational Affiliation
    The Second Affiliated Hospital of Chongqing Medical University
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Fan He
    Organizational Affiliation
    The Second Affiliated Hospital of Chongqing Medical University
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Jianguo Hu
    Organizational Affiliation
    The Second Affiliated Hospital of Chongqing Medical University
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Heng Zou
    Organizational Affiliation
    The Second Affiliated Hospital of Chongqing Medical University
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Huijia Chen
    Organizational Affiliation
    The Second Affiliated Hospital of Chongqing Medical University
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    18406834
    Citation
    Yu D, Wong YM, Cheong Y, Xia E, Li TC. Asherman syndrome--one century later. Fertil Steril. 2008 Apr;89(4):759-79. doi: 10.1016/j.fertnstert.2008.02.096.
    Results Reference
    background
    PubMed Identifier
    18995896
    Citation
    Ilancheran S, Moodley Y, Manuelpillai U. Human fetal membranes: a source of stem cells for tissue regeneration and repair? Placenta. 2009 Jan;30(1):2-10. doi: 10.1016/j.placenta.2008.09.009. Epub 2008 Nov 7.
    Results Reference
    background

    Learn more about this trial

    Human Amniotic Epithelial Cells for Asherman's Syndrome

    We'll reach out to this number within 24 hrs